Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma

References

• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–53.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430–2442.
   PubMed Web of Science ®Google Scholar
• Avivi I, Yekutiel N, Cohen I, et al. Diabetes, but not pre-diabetes, is associated with shorter time to second-line therapy and worse outcomes in patients with multiple myeloma. Leuk Lymphoma. 2021;62(11):2785–2792.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(2):230–269.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7.
   PubMed Web of Science ®Google Scholar
• Li J, Bao L, Xia Z, et al. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020;99(11):2589–2598.
   PubMed Web of Science ®Google Scholar
• Awada H, Thapa B, Awada H, et al. A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics. Cells. 2021;10(8):1961. doi:10.3390/cells10081961. PMID: 34440730; PMCID: PMC8391934.
   PubMed Web of Science ®Google Scholar
• Firth J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19(1):58–60.
   PubMed Web of Science ®Google Scholar
• Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, et al. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol. 2021;23(7):1429–1439.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Försti A, Houlston R, et al. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer. 2021;149(12):1980–1996.
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Mull N, Reagan JL, et al. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012;119(21):4845–50.
   PubMed Web of Science ®Google Scholar
• Zhang C, Sha Y, Liu H, et al. Type 2 diabetes mellitus does not increase the risk of multiple myeloma: a systematic review and meta-analysis. Transl Cancer Res. 2020;9(4):2884–2894.
   PubMed Web of Science ®Google Scholar
• Ali MA, Ahmed YA, Ibrahim A. Clinical challenges: myeloma and concomitant type 2 diabetes. South Asian J Cancer. 2013;02(4):290–5.
   Google Scholar
• Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–32.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
   PubMed Web of Science ®Google Scholar
• Organization WH. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva World Health Organization; 2006.
   Google Scholar
• Kim SY, Yoo CG, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011;26(2):264–7.
   PubMed Web of Science ®Google Scholar
• Das S, Yazit JN, Azmani N, et al. Multiple myeloma: challenges encountered and future options for better treatment. Int J Mol Sci. 2022;23(3):1649. doi:10.3390/ijms23031649. PMID: 35163567; PMCID: PMC8836148.
   PubMed Web of Science ®Google Scholar
• Ahmed YA, Eltayeb A. Clinical challenges: myeloma and concomitant type 2 diabetes. Int J Hematol Oncol Stem Cell Res. 2013;7(1):34–41.
   PubMedGoogle Scholar
• Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098–106.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60(6):1022–1032.
   PubMed Web of Science ®Google Scholar
• Gu Y, Yuan YH, Xu J, et al. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. Oncotarget. 2017;8(29):48350–48361.
   PubMedGoogle Scholar
• Chen YK, Han SM, Yang Y, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology. 2016;21(7):392–8.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Shao X. A combination of human embryonic stem cell-derived pancreatic endoderm transplant with LDHA-repressing miRNA Can attenuate high-Fat diet induced type II diabetes in mice. J Diabetes Res. 2015;2015:796912.
   PubMed Web of Science ®Google Scholar
• Peacock M. Calcium metabolism in health and disease. Clin J Am Soc Nephrol. 2010;5(Suppl 5):S23–30.
   PubMedGoogle Scholar
• Suh S, Bae JC, Jin SM, et al. Serum calcium changes and risk of type 2 diabetes mellitus in Asian population. Diabetes Res Clin Pract. 2017;133:109–114.
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158(17):1889–93.
   PubMedGoogle Scholar
• Griniūte R, Bumblyte IA. Clinical and laboratory features and prognostic implications in myeloma with and without renal impairment. Medicina (Kaunas). 2003;39(Suppl 1):41–7.
   PubMedGoogle Scholar
• Soleymanian T, Soleimani A, Musavi A, et al. Outcome of patients with multiple myeloma and renal failure on novel regimens. Saudi J Kidney Dis Transpl. 2016;27(2):335–40.
   PubMedGoogle Scholar
• Martínez Candela J, Sangrós González J, García Soidán FJ, et al. Chronic renal disease in spain: prevalence and related factors in persons with diabetes mellitus older than 64 years. Nefrologia. 2018;38(4):401–413.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Nakayama K, Ishikawa M, et al. High pretreatment plasma D-dimer levels are related to shorter overall survival in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2016;201:89–93.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Nakayama K, Ishikawa M, et al. High pre-treatment plasma D-dimer level as a potential prognostic biomarker for cervical carcinoma. Anticancer Res. 2016;36(6):2933–8.
   PubMed Web of Science ®Google Scholar
• Wang R, Liu R, Zhao L, et al. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients. Rev Esp Enferm Dig. 2017;109(7):503–509.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
   PubMed Web of Science ®Google Scholar
• Seebacher V, Polterauer S, Grimm C, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952–6.
   PubMed Web of Science ®Google Scholar
• Barazzoni R, Zanetti M, Davanzo G, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab. 2000;85(9):3121–5.
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, et al. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood. 2002;99(4):1305–13.
   PubMed Web of Science ®Google Scholar
• Antwi-Bafour S, Hammond S, Adjei JK, et al. A case-control study of prevalence of anemia among patients with type 2 diabetes. J Med Case Rep. 2016;10(1):110.
   PubMedGoogle Scholar
• Gradinaru D, Margina D, Ilie M, et al. Correlation between erythropoietin serum levels and erythrocyte susceptibility to lipid peroxidation in elderly with type 2 diabetes. Acta Physiol Hung. 2015;102(4):400–8.
   PubMedGoogle Scholar
• Bataille R, Annweiler C, Beauchet O. Multiple myeloma international staging system: “staging” or simply “aging” system. Clin Lymphoma Myeloma Leuk. 2013;13(6):635–7.
   PubMed Web of Science ®Google Scholar
• Lu J, Lu J, Liu A, et al. The applicability of the international staging system in Chinese patients with multiple myeloma receiving bortezomib or thalidomide-based regimens as induction therapy: a multicenter analysis. Biomed Res Int. 2015;2015:856704.
   PubMed Web of Science ®Google Scholar
• Iriuchishima H, Saitoh T, Handa H, et al. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. Eur J Haematol. 2015;94(2):145–51.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Thomsen H, Weinhold N, et al. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia. 2020;34(4):1187–1191.
   PubMed Web of Science ®Google Scholar
• NeamŢu MC, Avramescu ET, Marcu IR, et al. The correlation between insulin-like growth factor with glycemic control, glomerular filtration rate, blood pressure, hematological changes or body mass index in patients with type 2 diabetes mellitus. Rom J Morphol Embryol. 2017;58(3):857–861.
   PubMed Web of Science ®Google Scholar
• Ferlin M, Noraz N, Hertogh C, et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol. 2000;111(2):626–34.
   PubMed Web of Science ®Google Scholar
• Yu W, Cao D, Zhou H, et al. PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy. Oncol Rep. 2015;33(4):2086–92.
   PubMed Web of Science ®Google Scholar
• Ríos-Tamayo R, Lupiañez CB, Campa D, et al. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016;7(37):59029–59048.
   PubMedGoogle Scholar
• Zi FM, He JS, Li Y, et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett. 2015;356(2 Pt B):443–53.
   PubMed Web of Science ®Google Scholar